Switzerland-based Nouscom AG has recruited John McDonald, head of global business development at Novo Nordisk A/S, to its board as an independent director. This coincides with the advance into clinical studies of the company’s lead product, an off-the-shelf cancer vaccine. Before joining Novo Nordisk, Mr McDonald was head of business development at Biogen Inc, managing director at MPM Capital and vice president of business development at Millennium Pharmaceuticals Inc. He has degrees in both business administration and law.
Nouscom announced the appointment on 5 November 2018.
Copyright 2018 Evernow Publishing Ltd